Clinical responses are linked to high expression of PD-L1 in macrophages and dendritic cells in melanoma patients treated with a combination of anti-CTLA-4 and anti-PD-1 and in ovarian cancer patients treated with anti-PD-1, even if in the latter case the results are not statistically significant due to poor responses (87). Here, PDCD1 is linked to ovarian carcinoma.